553 related articles for article (PubMed ID: 16553504)
1. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ
Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504
[TBL] [Abstract][Full Text] [Related]
2. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia.
Olsson AG; Istad H; Luurila O; Ose L; Stender S; Tuomilehto J; Wiklund O; Southworth H; Pears J; Wilpshaar JW;
Am Heart J; 2002 Dec; 144(6):1044-51. PubMed ID: 12486429
[TBL] [Abstract][Full Text] [Related]
3. Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia.
Davidson MH
Expert Opin Investig Drugs; 2002 Jan; 11(1):125-41. PubMed ID: 11772327
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial.
Brown WV; Bays HE; Hassman DR; McKenney J; Chitra R; Hutchinson H; Miller E;
Am Heart J; 2002 Dec; 144(6):1036-43. PubMed ID: 12486428
[TBL] [Abstract][Full Text] [Related]
5. Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia.
Davidson MH
Expert Opin Investig Drugs; 2002 Mar; 11(3):125-41. PubMed ID: 12769127
[TBL] [Abstract][Full Text] [Related]
6. Statin therapy: rationale for a new agent, rosuvastatin.
Korlipara K
Int J Clin Pract; 2002 Jun; 56(5):379-87. PubMed ID: 12137448
[TBL] [Abstract][Full Text] [Related]
7. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
[TBL] [Abstract][Full Text] [Related]
8. Management of dyslipidemia in the high-risk patient.
Stein EA
Am Heart J; 2002 Dec; 144(6 Suppl):S43-50. PubMed ID: 12486415
[TBL] [Abstract][Full Text] [Related]
9. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Breuer HW
Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
[TBL] [Abstract][Full Text] [Related]
10. Managing dyslipidemia in the high-risk patient.
Stein EA
Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and cost of HMG-CoA reductase inhibitors in the treatment of patients with primary hyperlipidemia.
Perreault S; Levinton C; Le Lorier J
Can J Clin Pharmacol; 2000; 7(3):144-54. PubMed ID: 11044760
[TBL] [Abstract][Full Text] [Related]
12. Clinical rationale for rosuvastatin, a potent new HMG-CoA reductase inhibitor.
Hanefeld M
Int J Clin Pract; 2001; 55(6):399-405. PubMed ID: 11501230
[TBL] [Abstract][Full Text] [Related]
13. Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia.
Cheng-Lai A
Heart Dis; 2003; 5(1):72-8. PubMed ID: 12549990
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis.
Berry DA; Berry SM; McKellar J; Pearson TA
Am Heart J; 2003 Jun; 145(6):1036-45. PubMed ID: 12796760
[TBL] [Abstract][Full Text] [Related]
15. Relative effectiveness of niacin and lovastatin for treatment of dyslipidemias in a health maintenance organization.
O'Connor PJ; Rush WA; Trence DL
J Fam Pract; 1997 May; 44(5):462-7. PubMed ID: 9152263
[TBL] [Abstract][Full Text] [Related]
16. Rosuvastatin--a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40 mg doses in dyslipidemic patients.
Schuster H
Cardiology; 2003; 99(3):126-39. PubMed ID: 12824720
[TBL] [Abstract][Full Text] [Related]
17. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
[TBL] [Abstract][Full Text] [Related]
18. The power of statins: aggressive lipid lowering.
Stein EA
Clin Cardiol; 2003 Apr; 26(4 Suppl 3):III25-31. PubMed ID: 12708636
[TBL] [Abstract][Full Text] [Related]
19. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study.
Paoletti R; Fahmy M; Mahla G; Mizan J; Southworth H
J Cardiovasc Risk; 2001 Dec; 8(6):383-90. PubMed ID: 11873095
[TBL] [Abstract][Full Text] [Related]
20. Addressing the challenge.
Olsson AG
Eur Heart J; 1998 Oct; 19 Suppl M():M29-35. PubMed ID: 9821014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
